Benitec Biopharma Boosts Cash by $87M After $100M Offering, Mitigates Going Concern Risk
BNTC sits 18% above its 52-week low of $9.85.
Summary
Benitec Biopharma reported a substantial increase in cash to $184.8 million following a $100 million capital raise, reducing its operating cash burn and addressing prior internal control weaknesses, providing a stronger financial foundation for its clinical programs.
Key Events · Financing and Capital Events · BNTC
-
$100 Million Capital Raise Completed
The company completed a $100 million capital raise in November 2025, consisting of an underwritten offering and a concurrent registered direct offering to institutional investors at $13.50 per share. This significantly boosted the cash reserves.
-
Cash Position Doubled, Going Concern Mitigated
Cash and cash equivalents increased to $184.8 million as of March 31, 2026, from $97.7 million in June 2025. Management now estimates cash is sufficient to fund operations for at least the next twelve months, mitigating previous going concern risks.
-
Reduced Operating Cash Burn
Net cash used in operating activities decreased to $11.6 million for the nine months ended March 31, 2026, compared to $15.4 million in the prior year period, indicating improved operational efficiency.
-
Material Weakness in Internal Controls Remedied
The previously reported material weakness in internal control over financial reporting, related to share-based compensation calculations, has been remediated as of December 31, 2025.
Analysis · BNTC · Life Sciences
Benitec Biopharma significantly strengthened its financial position, reporting $184.8 million in cash and cash equivalents as of March 31, 2026, up from $97.7 million in June 2025. This improvement is primarily due to a $100 million capital raise in November 2025, which included an underwritten offering and a direct offering to institutional investors at $13.50 per share. The company also reduced its operating cash burn for the nine months ended March 31, 2026, and successfully remediated a material weakness in its internal controls related to share-based compensation. These financial improvements provide a longer runway for its clinical development programs, particularly BB-301, which recently reported positive interim Phase 1b/2a clinical trial results.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTC was trading at $11.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.2M. The 52-week trading range was $9.85 to $17.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.